Optimi Health Corp. (OPTH) Form 6-K — Jun 29, 2026
Optimi Health Corp. announced the completion of its third commercial shipment of 5mg psilocybin capsules to Australia for the treatment of treatment-resistant depression. The shipment contained 1,000 capsules, marking continued progress since the product launch in September 2025. The company benefits from Australia's status as the first country to reschedule psilocybin as a medicine, with products now reimbursed by public and private payers including the Department of Veterans’ Affairs and Medibank.
Key figures
- Dosage
- 5mg
- Shipment Count
- 3
- Shipment Quantity
- 1,000 capsules
- Clinicians Trained
- 750
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.